Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiotensinogen mRNA is the messenger RNA produced from the angiotensinogen (AGT) gene, which encodes the angiotensinogen protein—a precursor to angiotensin peptides. Angiotensinogen mRNA itself is not a drug target, receptor, enzyme, transporter, or protein, but its expression levels are studied in relation to regulation of angiotensinogen synthesis in tissues such as the liver and kidney[4]. The manipulation or measurement of angiotensinogen mRNA is primarily relevant in experimental settings to understand gene expression responses in hypertension and tissue-specific angiotensinogen production[4][5]. The canonical therapeutic target for angiotensin-related pathways is typically the angiotensinogen protein (AGT) or downstream receptors (e.g., the angiotensin II type 1 receptor, AT1R), not the mRNA itself[8][1]. For structured drug target annotations, selecting “angiotensinogen” (AGT) is scientifically accurate; the mRNA is not considered a true therapeutic target. If you intend to annotate a drug target, use "Angiotensinogen" (AGT), not "Angiotensinogen mRNA". Angiotensinogen is a glycoprotein precursor to all angiotensin peptides and is a member of the non-inhibitory serpin superfamily[3][5][8]. Regulated expression of angiotensinogen mRNA is key to homeostatic control of local and systemic Renin-Angiotensin-Aldosterone System (RAAS) activity, with roles in blood pressure regulation, sodium homeostasis, and cardiovascular pathophysiology[3][4]. Pathological increases in angiotensinogen mRNA precede excess angiotensin II formation implicated in hypertension and cardiovascular disease[4]. AGT is not itself a receptor, enzyme, or transporter, but is sometimes targeted by antisense oligonucleotides or RNAi experimentally to reduce protein levels and downstream angiotensin production[3][4]. Angiotensinogen mRNA is not a canonical therapeutic target. The protein product, "angiotensinogen," may be annotated as a target, but the mRNA transcript should not. Enter "Angiotensinogen" (AGT), not "Angiotensinogen mRNA," for structured target databases[8][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiotensinogen mRNA (AGT mRNA).